A team of European and U.S. researchers have found that a new vaccine strategy tested in mice provides improved protection from tuberculosis (TB) infection than the vaccine currently used in humans, known as BCG. Their findings were published online on January 23rd in the journal Nature Medicine.
In this study, researchers at the Statens Serum Institut in Denmark combined two proteins that had previously been tested with a new component, a stress response protein that Mtb, the bacteria that causes TB, produces during latent infection. This three-component vaccine, known as H56, protected against initial illness, controlled reactivation of latent infection and reduced Mtb levels in the lungs more effectively than BCG alone.
For more information, see the NIAID media availability at http://www.niaid.nih.gov/news/newsreleases/2011/Pages/TBvaccineCollaboration.aspx.
Media Availability: Collaboration Fuels Promising New Approach to a TB Vaccine
No hay comentarios:
Publicar un comentario